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Abstract 
Background: Several epidemiological and cohort studies suggest that regular low-dose aspirin use independently 
reduces the long-term incidence and risk of colorectal cancer deaths by approximately 20%. However, there are also 
risks to aspirin use, mainly gastrointestinal bleeding and haemorrhagic stroke. Making informed decisions depends 
on the ability to understand and weigh up benefits and risks of available options. A decision aid to support people 
to consider aspirin therapy alongside participation in the NHS bowel cancer screening programme may have an 
additional impact on colorectal cancer prevention. This study aims to develop and user-test a brief decision aid about 
aspirin to enable informed decision-making for colorectal screening-eligible members of the public.
Methods: We undertook a qualitative study to develop an aspirin decision aid leaflet to support bowel screening 
responders in deciding whether to take aspirin to reduce their risk of colorectal cancer. The iterative development 
process involved two focus groups with public members aged 60–74 years (n = 14) and interviews with clinicians 
(n = 10). Interviews (n = 11) were used to evaluate its utility for decision-making. Analysis was conducted using a 
framework approach.
Results: Overall, participants found the decision aid acceptable and useful to facilitate decision-making. They 
expressed a need for individualised risk information, more detail about the potential risks of aspirin, and preferred 
risk information presented in pictograms when offered different options. Implementation pathways were discussed, 
including the possibility of involving different clinicians in the process such as GPs and/or community pharmacists. A 
range of potentially effective timepoints for sending out the decision aid were identified.
Conclusion: An acceptable and usable decision aid was developed to support decisions about aspirin use to prevent 
colorectal cancer.
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Background
Colorectal cancer is one of the most common cancers in 
the UK with over 41,000 new cases diagnosed and nearly 
16,000 deaths, each year [1]. The biennial faecal occult 
blood testing prevents colorectal cancer from develop-
ing by identifying it at an early stage being associated 
with a reduction in colorectal cancer deaths of approxi-
mately 16%  [2]. Currently, the Faecal Immunochemical 
Test (FIT) is used as standard in the UK Bowel screen-
ing programmes. This is due to higher sensitivity of the 
quantitative FIT test in detecting advanced neoplasia and 
Open Access
*Correspondence:  DolwaniS@cardiff.ac.uk
1 Division of Population Medicine, Cardiff University, Cardiff, UK
Full list of author information is available at the end of the article
Page 2 of 10Semedo et al. BMC Med Inform Decis Mak          (2021) 21:165 
colorectal cancer, easier handling and assessment and 
potentially higher uptake [3, 4].
Approaches to reduce colorectal cancer incidence and 
reduce individual risk have mainly focused on increas-
ing participation in colorectal screening as well as dietary 
and lifestyle strategies for behaviours such as healthy eat-
ing, drinking less alcohol and being more active  [3]. A 
recent approach in primary care focuses on chemopre-
vention, prescribing low-dose aspirin to lower the risks 
by delaying and preventing cancer development and 
mortality  [5–7].
The overall benefit from taking low-dose aspirin is sim-
ilar to screening by colonoscopy for reducing cancer inci-
dence and mortality with aspirin being more effective for 
proximal colon cancers  [5]. Colorectal screening appears 
most effective for distal colon cancers [6]. Alongside 
screening, aspirin therapy may potentially have an addi-
tional impact on the prevention of colorectal cancer [6, 
7]. However, this approach has not yet been tested.
The Australian National Health and Medical Research 
Council and the United States Preventive Services Task 
Force (USPTF) recently updated their recommendations 
based on clinical evidence documenting the effects of 
daily low-dose (75–300  mg) aspirin therapy on colorec-
tal cancer incidence and mortality [8, 9]. This evidence 
derived from pooled analyses of individual patient data 
in primary and secondary cardiovascular disease and 
adenoma prevention trials, describing the risks asso-
ciated with aspirin use, gastrointestinal bleeding and 
haemorrhagic stroke. These findings indicate a reduction 
in the incidence of colorectal cancer suggesting a preven-
tive effect of aspirin after 5 to 10 years of continued use. 
The health benefit appears to be largest for adults aged 
between 50 and 70  years [8]. Despite recommendations 
for population use of low-dose aspirin in prevention of 
colorectal cancer in some countries [8], this is not cur-
rently endorsed in the UK. Further, there is no patient-
facing information to facilitate individual decisions. 
Combining the two-independent risk-reduction strate-
gies, aspirin and colorectal screening, with a decision aid 
to support informed choice about taking aspirin could 
optimise behavioural and clinical outcomes in screening-
eligible adults [6, 10, 11].
Shared decision-making is a priority for clinicians and 
policy makers worldwide, and one of the main compo-
nents of patient-centred care [12]. This is reflected in 
the development of decision aids, informational tools 
that support individuals making complex treatment or 
screening decisions by providing information aligned 
with individual values and preferences for risk communi-
cation [13, 14].
Deciding whether to take aspirin could be supported 
by shared decision-making between the patient and 
their clinician, based on individualised risk factors. This 
would help people weigh up the harms and benefits of 
taking aspirin as a preventive strategy against colorec-
tal cancer.
Our aim was to develop and user-test a brief deci-
sion aid for acceptability and utility, to enable informed 
decision-making for preventive low-dose aspirin use 
that could be implemented alongside the UK bowel 
cancer screening programmes.
Methods
Decision aid development and user‑testing process
The Cardiff University School of Medicine Institu-
tional Review Board granted ethical approval (refer-
ence 18/23). The present study was conducted over two 
phases, development, and user-testing, from Septem-
ber 2018 to August 2019 (Fig. 1). In phase one (develop-
ment), we first identified and summarised the scientific 
evidence reporting the risks/benefits of taking aspirin 
to prevent colorectal cancer, derived from existing clin-
ical guidelines/systematic reviews of randomised con-
trolled trials in healthy and clinical populations.
Clinical evidence in summary form was agreed by a 
scientific reference group of national experts and clini-
cal professionals (n = 4). The prototype was developed 
based on the scientific reference group recommenda-
tions and considering the type of information people 
might need to decide.
Its content was developed according to the Inter-
national Patient Decision Aids Criteria by presenting 
clear probabilities of outcomes to help individuals bal-
ance options, ensuring decision-making is informed 
and based on personal preferences [15].
The prototype decision aid was presented in a fre-
quently asked questions format, tailored according to 
age, three categories (60–64; 65–69; 70–74) within the 
eligible screening ages and gender. It was then shown 
to members of the public (focus groups) and clinicians 
(interviews) for discussion.
The decision aid content and format were further 
informed by incorporating participants’ feedback on 
the draft prototype, information needs, and preferences 
for risk communication.
Phase two (user-testing) gained user feedback 
through qualitative interviews with public members. 
Modifications to the content of the prototype followed 
an iterative process, informed by participants’ feedback 
on acceptability and utility for decision-making in both 
phases. The content was improved to increase readabil-
ity and was accredited for clarity of information with a 
Crystal Mark by the Plain English Campaign [16].
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Patient and public involvement
The present study follows the National Institute for 
Health and Research UK standards for effective patient 
and public involvement (PPI) in research  [17] (Table 1).
Phase one: brief decision aid development
Participants, materials and procedure
Members of the public Inclusion criteria were colorectal 
screening responders in South Wales, aged 60–74 years, 
who could read and speak English. Individuals were 
recruited through existing community links, Bowel 
Screening Wales, Healthwise Wales and Tenovus Cancer 
Care (Appendix).
A covering letter, information sheet and consent form 
were sent to participants before the focus groups. Partici-
pants were allocated to one of two focus groups of mixed 
age and gender which were audio-recorded.
The focus groups were facilitated by experienced 
researchers (KL, SS) and started with a brief presenta-
tion (LS) explaining the aim of the study, the decision 
aid concept and the importance of informed decision-
making. Subsequently, different paper-based examples of 
existing decision aids were shown to participants. Finally, 
participants were given a copy of the aspirin decision aid 
prototype (large print, A3) and time to process the infor-
mation before discussing the content, format, useful-
ness for decision-making, and barriers and facilitators of 
Evidence synthesis 
Scientific reference group 
consensus            






(acceptability and utility) Modified prototype 






Fig. 1 Flow chart showing the iterative process of the decision aid development
Table 1 Standards for effective PPI in research
UK standards for PPI in research
(a) Inclusive opportunities. The Wales Cancer Research Centre has a network of Research Partners (RP) Patients and members of the public who 
are actively involved in planning and management of research. They offer practical PPI support and advice to researchers. The study involved 
members of the public for whom the research may prove beneficial
(b) Working together. PPI input was vital from the very beginning of this research and public-facing materials were developed in collaboration with 
our PPI partner and co-author (KS) in project management meetings
(c) Support and learning. PPI contributions were fully recorded and evidenced support and learning in this research, by the RP and by researchers
(d) Communications. Developing effective methods of communicating and presenting the risks and benefits of taking aspirin to reduce risk of 
colorectal cancer, in plain language available in formats to suit individual needs was made possible because of the PPI feedback
(e) Impact. A study summary was made available to participants, the funder (Tenovus Cancer Care) and Bowel Screening Wales. This acknowl-
edged the impact of PPI contributions
(f ) Governance. PPI RP input was integral to this research We also sought public views through discussions with a Citizens’ Jury [18] who helped 
explore attitudes towards the role of medicines in maintaining health, using low dose aspirin as a case study, highlighting the importance of 
providing information to inform decision-making
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aspirin use as a preventive strategy for colorectal cancer 
(see Additional file 2-public members focus group topic 
guide).
Clinicians Clinicians were invited to participate because 
of their area of expertise and because they may be the 
first point of contact for some individuals and therefore 
potentially the ones who may discuss the decision aid with 
individuals in the future. A covering letter, information 
sheet and consent form were sent to a purposeful sample 
of clinicians who were involved in different areas related 
to the prevention, diagnosis, and management of colorec-
tal cancer, practising in Wales. A copy of the decision aid 
prototype was sent to clinicians before the interviews to 
ensure familiarity with the information.
Semi-structured interviews were conducted and audio-
recorded either face-to-face in a preferred location (place 
of work) or, due to practical constraints of time and geo-
graphical distance, by telephone. Feedback was sought 
from clinicians on the usefulness of the decision aid and 
potential implementation strategies alongside the bowel 
screening programme (see Additional file 2: Table 2).
Phase two: user‑testing the brief decision aid
Participants, materials and procedure
Public members Interview participants were selected 
purposefully by including a relevant demographic for the 
screening programme ensuring variation in age, gender 
and geographic location. Inclusion criteria and recruit-
ment strategies were the same as in phase one. Interviews 
were conducted according to participants’ preferences, 
either face-to-face in a university meeting room or by 
telephone. Before interviews, participants were sent the 
refined prototype and two risk pictograms, one with addi-
tional figures to represent colorectal cancer and bleeding 
risks and one without. Interview topic guide (see Addi-
tional file 2: user interview topic guide) included informa-
tion provision, clarity and understanding of information, 
any sections to be improved, risk pictograms, general for-
mat, and views about optimal ways of implementing the 
decision aid.
Data analysis
Data analysis followed the same approach in both phases. 
A qualitative design was used for data gathering and iter-
ative development of the brief decision aid. Focus group 
and interview recordings were transcribed verbatim, 
managed using NVivo  [19] qualitative data analysis soft-
ware (Version 12, 2018) and analysed using a framework 
approach [20]. Analysis involved (1) familiarisation with 
the data through comprehensive reading of transcripts, 
(2) identifying a coding framework by drawing on ques-
tions included in the topic guides to capture emerging 
concepts (LS and KL). Codes related to specific concepts 
were charted (3) and subsequently summarised, inter-
preted and any discrepancies resolved by consensus (4).
LS primarily coded the data and a sample (20%) of the 
transcripts was also coded by KL. Quotes were selected 
illustrating identified themes. Changes were made to the 
decision aid based on participant feedback, information 
needs and preferences for risk communication.
Results
Brief decision aid development and user‑testing
Focus group participants had a mean age of 64.71 years, 
mostly highly educated, 50% male. Clinicians were of var-
ied backgrounds, 50% male. Interview participants had a 
mean age of 67.09 years, mostly male (60%) and 50% were 
currently taking aspirin (Table 2).
Phase one: development
Public members’ feedback on the decision aid prototype
Participants understood the content of the prototype in 
terms of the risks (bleeding events) and benefits of tak-
ing aspirin (reduction in colorectal cancer cases). Some 
expressed concerns over the severity of risks and per-
ceived reduced benefits, whilst others did not. Partici-
pants perceived information gaps in the prototype that 
needed addressing to increase the utility of the decision 
aid. These included the consequences of bleeding events, 
further information on low-dose aspirin (e.g. dose, side 
effects, and optimum age to start aspirin) and sources of 
available clinical evidence used to develop the prototype 
and mortality information (see Additional file 2: Table 1).
In terms of preferences for risk communication, there 
was consensus that risk information should be changed 
to pictograms to decrease the amount of text in the pro-
totype. Participants appreciated that the prototype was 
personalised for age and gender but stated that individual 
tailoring for specific factors such as family history and 
medical history would be helpful.
Participants also mentioned wanting to discuss individ-
ual risk profiles with a clinician.
I think that without that [ tailored risk], I would 
want to be discussing it with my doctor… you can 
only answer it on a statistical average basis… 
because everyone’s colorectal cancer [risk] will be 
different…. (Male, FG1, Participant 2).
Participants suggested simplifying the language and 
developing supplementary information (e.g. website link) 
for people who desired to know more.
Views differed when considering implementation path-
ways alongside the bowel screening programme. Whilst 
some believed that people could benefit more if the deci-
sion aid was introduced before the eligible screening age, 
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e.g. through a public health campaign, others thought 
that sending the aspirin information alongside the 
screening invitation could encourage people to consider 
both in tandem. Individuals also stated that they would 
want to discuss with other healthcare professionals (e.g. 
community pharmacists) to relieve pressures on GPs’ 
time.
When exploring potential decisions to take aspirin, 
given the information provided, most individuals said 
that they would not take aspirin for now but would dis-
cuss their options with their GP in the future. Some 
expressed confidence in their doctors to support them 
making future decisions.
Table 2 Participant demographics and characteristics
n/a not applicable
Study phase Phase 1 Phase 2














Male 3 4 5 6
Female 4 3 5 5
Highest level of education n/a
Bachelors ‘degree/masters/PhD 6 6 3
Further education but not degree 1 1 3
Finished school at or before age fifteen 2
Completed A-levels or equivalent 1
CSEs, O-levels or equivalent 1
Missing 1
Employment status n/a
Employed full-time 1 2
Employed part-time 1 2
Retired 5 5 8
Missing 1




Specialist screening practitioner 3
University Health Board n/a n/a n/a
Aneurin Bevan 1
Cardiff & Vale 7
Cwm Taff 1
Hywel Da 1
Home living arrangements n/a
Own outright 7 7 9




No 7 6 5
Missing 1
Area
South Wales 7 7 10 6
North Wales 5
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Generally, participants thought that the decision aid 
was useful to inform decision-making.
…I think it covers the main points for most people 
…it does help them to make their own decision. I 
don’t like taking tablets, that’s absolutely fine, but it 
makes you think of the points you’ve got to consider. 
(Female, FG1, Participant 3).
Most participants were satisfied with the short leaflet 
format, although others thought that a booklet format 
would help to present the information. Some preferred a 
paper-based prototype whilst others would rather access 
information online.
Clinicians’ feedback on the prototype
Clinicians commented on specific information they felt 
was useful to include to improve decision quality, build-
ing on the information requested by public members (see 
Additional file 2: Table 2). This included further informa-
tion about aspirin stating the consequences of bleeding 
risks and using simpler language to explain information. 
Clinicians felt it was important to clarify the purpose of 
information to potential users. Some thought the risk 
information was well presented, and others felt that pic-
tograms would increase the level of engagement with the 
information.
A few clinicians thought that risk stratification was a 
complex subject to address due to the impact of other 
factors on one’s level of risk.
…it is a very much average…I don’t think you can 
give a very specific risk to every single person that 
you’ll see, because you’ve got factors such as age, 
diet, lifestyle, family history and also things like past 
medical history, other treatments they’re taking… 
(Consultant gastroenterologist 1)
They believed that the prototype included useful infor-
mation for people to decide whether to take aspirin and 
conveyed the need to develop such information for peo-
ple’s benefit.
They thought that the format/length of the prototype 
was good, but it would be useful to break it down into 
sections to facilitate its use.
Discussions about implementation pathways con-
cerned the best timing to send the decision aid, shared 
decision-making, and potential barriers to implemen-
tation. Clinicians thought that the information should 
be communicated through primary care, others said it 
could be sent with the initial bowel screening invitation 
or after a positive screening test result. They also agreed 
that the GP would represent a safety net to discuss 
options but that it would be important for different clini-
cians to be involved, by ‘making every contact count’[21]. 
Most clinicians felt confident to discuss the information 
though some felt that they would need more informa-
tion about aspirin to engage in shared decision-making. 
Potential barriers to implementation included addressing 
time constraints and resourcing for clinicians.
Phase two: user‑testing
Users’ feedback on the modified prototype
The modified prototype was received positively by poten-
tial users. Overall, participants thought that it was con-
cise, clear and understandable with the right level of 
language.
Minor improvements to the content were suggested 
to supplement the information in the prototype such as 
including information for people already using aspirin 
and more information on bleeding events (see Additional 
file  2: Table  3). Whilst participants thought that risk 
information was conveyed well, they preferred the picto-
gram with no images and suggested presenting the risks 
of colorectal cancer and bleeding separately.
Generally, participants were pleased with the modified 
prototype. Only one participant was unsure about how 
the decision aid would be used.
I think I least like this sort of confusion about 
whether you could just take it or go and see the GP 
(Female, Participant 2)
The strengths of the modified prototype were discussed 
and included personalisation to age groups.
… I like how it’s presented for my age group… it’s 
more directive to me… (Male, Participant 11)
Participants welcomed the information regarding the 
importance of considering both screening and aspirin 
as strategies for colorectal cancer risk-reduction and 
thought that both aspects would likely influence future 
screening uptake.
A few participants who were taking aspirin for other 
reasons stated that the information reassured them to 
continue taking aspirin.
…so, what I quite liked about it was that this has 
sort of reassured me to carry on taking aspirin so I… 
personally found it useful. (Male, Participant 6)
Others mentioned that they would further discuss it 
with their clinician due to health problems or because 
they disliked taking medication. Some said that they 
would be inclined to take it if it benefitted them.
Participants were pleased with the modified prototype 
format in terms of layout, length, order, graphics, font 
size, colours. They thought it followed a logical structure 
by explaining and presenting options that would support 
potential decisions.
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As in phase one, there were different views regarding 
the best time point to implement the decision aid.
The user‑tested final decision aid
The brief decision aid (Additional file  1-available on 
request) is structured in four main parts over four A4 
pages (Fig. 2).
Discussion
In the absence of information for the use of low-dose 
therapeutic aspirin use to support decision-making, we 
developed and tested a brief decision aid presenting the 
risks and benefits of aspirin as a preventive strategy for 
colorectal cancer, which could be used and implemented 
in current population and healthcare settings. The deci-
sion aid was developed iteratively, by including the best 
available clinical evidence and its content and format 
were modified based on participants’ information needs 
and preferences for risk communication. Implementa-
tion strategies were discussed, including the best timing 
to send the decision aid and the need to involve different 
clinicians in the process. However, there were different 
views regarding when to implement the decision aid.
Strengths of the decision aid relate to the rigorous 
development process which followed International 
Patient Decision Aid guidelines  [15, 23]. Likewise, pub-
lic and patient input adhered to good practice [17]. The 
decision aid was edited to improve user understanding 
and accredited with a ‘Crystal Mark’ by the Plain English 
Campaign [16]. The decision aid content was tailored 
based on age and gender, however, participants wanted 
individualised risk information. When considering deci-
sions about medication use, the benefits may not clearly 
outweigh the risks for all patients, therefore individuals 
were encouraged in the decision aid to directly discuss 
options with their GP or community pharmacist.
We acknowledge potential limitations in this develop-
ment study. The sample included individuals who could 
read and speak English and educated to degree level, 
potentially not entirely representative of people receiv-
ing this information in the future. Wider field-testing of 
the decision aid should therefore involve a more diverse 
group of users and potentially be adapted for use with 
underserved groups (e.g. low literacy) to reduce inequali-
ties in healthcare communication. Further refinement of 
the decision aid may also consider specific groups who 
may benefit from aspirin therapy.
The decision aid was designed to include balanced 
information whilst avoiding cognitive burden [25]. 
Participants’ requests for key information were mostly 
fulfilled and, where appropriate, signposting to the 
Part 3
Elicits individual values and preferences and assists the patient in 
the decision-making process. 
Part 4
Provides an opportunity for people to write any concerns they might have 
and might want to discuss with a healthcare professional.  
Part 2
Presents options and outcomes for risks of developing bowel cancer and 
bleeding so people can weigh the options of not taking versus taking aspirin. 
Part 1
States for whom it is intended, followed by information about colorectal cancer and low-
dose aspirin. Explains the risks and benefits of taking low-dose aspirin and emphasises the 
importance of considering taking part in colorectal screening to achieve better outcomes. 
Fig. 2 Different sections of the final decision aid informed by the latest clinical evidence
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product information (e.g. side effects) applied. Addi-
tional multilevel material on a website or paper may be 
developed to explain specific themes.
Existing studies on aspirin use report mixed findings 
that merit further investigation [26–30]. The USPTF 
guidelines suggest routine prescribing of aspirin in 
patients presenting with advanced colorectal polyps 
unless contraindicated [9]. Despite this, studies still 
report low aspirin use in these populations [26]. Other 
evidence suggests that aspirin may impact on FIT per-
formance. Studies have reported either a potential 
higher risk of false positive FIT results, no changes in 
FIT diagnostic accuracy in patients presenting with 
gastrointestinal symptoms or an increase in FIT sensi-
tivity by aspirin use [27–30]. There is also uncertainty 
about the optimum dose for low-dose aspirin use in the 
prevention of colorectal cancer. Available evidence sug-
gests that an effective dose of aspirin would depend on 
factors such as body weight [31].
To our knowledge, this is the first study to report 
the development and user-testing of a decision aid for 
aspirin to prevent colorectal cancer for a bowel screen-
ing population. It is vital to consider implementation 
strategies including alongside a screening programme. 
The decision aid could be used without the presence of 
a clinician and/or as a component of shared decision-
making in a primary care setting by ensuring tailored 
information is communicated effectively and poten-
tially in combination with individualised risk calcula-
tors [32–35]. If the decision aid is sent with the initial 
screening invitation or following a positive test result, 
discussions could involve the GP and/or community 
pharmacist or specialist screening practitioner/colo-
noscopist, respectively. Resources such as education, 
training needs and costs would be required to success-
fully embed the decision aid within the bowel screening 
programme.
Implementation strategies for the decision aid warrant 
further investigation which could be done by field test-
ing the decision aid. Examination of how the decision aid 
might influence behavioural intentions (aspirin use and 
screening) and its impact on screening uptake also need 
to be explored. A recent Australian study investigated 
specific risk presentation formats and intentions to take 
aspirin to prevent colorectal cancer but did not examine 
understanding or attitudes to aspirin use or screening 
intentions [36].
In the future, the evaluation of a combined risk-reduc-
tion strategy of aspirin, screening, diet and lifestyle may 
directly benefit subsequent screening invitees in terms of 
improved behavioural and clinical outcomes.
Conclusions
An acceptable and usable decision aid was developed to 
support decisions about aspirin use to prevent colorec-
tal cancer. Field testing of the decision aid would assess 
the feasibility of its use alongside the bowel screening 
programme.
Appendix
Bowel Screening Wales is responsible for the NHS 
bowel screening programme in Wales which is cur-
rently offered to individuals aged 60–74 years old. The 
screening engagement team (SET) work across Wales 
to improve knowledge and raise awareness of screen-
ing within local communities. This involves delivering 
community training, providing resources, attending 
networking events and running local initiatives with 
third-sector organisations across Wales. The team has 
links to participant networks to improve the develop-
ment of public information, service user experience and 
screening uptake across all the screening programmes 
in Wales.
The Tenovus Cancer Care research network is a 500 
strong list of individuals who have been diagnosed with 
or indirectly affected by cancer (patients, carers) includ-
ing people who have an interest in research with no 
background of cancer. The research network are sent 
information about studies every four months. Potential 
participants will register interest via the telephone num-
ber or email address provided in the newsletter. Infor-
mation about studies being carried out are sent through 
newsletters.
Healthwise Wales (HHW) represents a project funded 
by Health and Care Research in Wales aimed at improv-
ing the health and well-being of the population in Wales. 
The project team includes Cardiff and Swansea univer-
sities (SAIL and UKSerRP), health and care research 
Wales and patient and public involvement to involve 
public members in consultation and collaboration with 
project management. Healthwise Wales has a register 
of over 40,000 who are part of a cohort of longitudinal 
data on health, lifestyle and health services linked to 
routinely available healthcare data in Wales. People are 
sent information approximately every 6  months about 
opportunities to engage in research across five main 
themes (1) impact of social inequalities on health and 
well-being (2) environment, neighbourhood and health, 
(3) maintenance of health and well-being in the working 
age population (4) wellbeing in later life and (5) innova-
tion in health and social care services. Patient and public 
involvement.
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